AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06139523 — intervention group
Intervention type: DEVICE
Intervention: Investigational contact OCT system
Description: Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
Study NCT06139523 — intervention group
Intervention type: DEVICE
Intervention: Investigational noncontact OCT system:
Description: The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~* Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~* The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety.
Study NCT05247996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles.
Study NCT05247996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-target Drug Therapy
Description: Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
Study NCT05247996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunocheckpoint Inhibitor Therapy
Description: Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
Study NCT05247996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Intravenous Chemotherapy
Description: GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
Study NCT05387096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Definitive multi-faceted intervention consisting of several components
Description: The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 3-6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.
Study NCT05387096 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire in addition to standard care.
Study NCT04875221 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Connectivity-based neurofeedback
Description: Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
Study NCT04875221 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Connectivity-based neurofeedback
Description: Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
Study NCT05275959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China
Description: Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance.
Study NCT05770193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 _75% tension and the tails will be applied toward the ribs.
Study NCT05312138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
Study NCT05312138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation
Description: The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
Study NCT05121311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NeoprediX B1 algorithm
Description: Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
Study NCT05505110 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Seeding
Description: Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
Study NCT05505110 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sterile Swab
Description: Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the control group will have their nasal cavity swabbed with a sterile swab.
Study NCT06479759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108 antibody and sintilimab
Description: Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab
Study NCT06479759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108 antibody and sintilimab and chemotherapy
Description: Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
Study NCT04195984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-thos® valve and transapical delivery system
Description: Transcatheter mitral valve replacement system
Study NCT06118359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Support Interhospital Transfer Decisions (SITe)
Description: The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
Study NCT05075824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight >= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight >= 100 kg). Dosing schedule will be as per Arm Description.
Study NCT05075824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
Study NCT04934176 — intervention group
Intervention type: OTHER
Intervention: Psychosocial scales/questionnaires
Description: We will use three psychosocial scales/questionnaires for this patient population to gauge patients' perceptions of the impact of their paralysis and their recovery. The questionnaires will be completed by the patients at baseline, and 18 months after surgery. Moreover, we also will compare patient perceptions to the patient-related responses with clinical scoring made by the surgeons using the eFACE,6 Face-Gram/Emotrics12 software, and the 3D dynamic measures.
Study NCT04934176 — intervention group
Intervention type: OTHER
Intervention: 3D Facial Measurements
Description: 3D dynamic (objective) facial movement data will be collected first (estimated time 1 hour), followed by static 3D photographic data (estimated time 15 minutes), and then video data of the different facial animations (estimated time 15 minutes).
Study NCT04998123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeizureStop Device
Description: Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.
Study NCT04998123 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SeizureStop Device
Description: Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.
Study NCT06283550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Abrocitinib will be available in 100 mg strength tablet
Study NCT06283550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abrocitinib 200 mg
Description: Abrocitinib will be available in 100 mg strength tablet
Study NCT06283550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: Abrocitinib will be available in 100 mg strength tablet
Study NCT06283550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT05197192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v.
Study NCT05166317 — intervention group
Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study NCT06275906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and moderate intensity physical exercise (outdoor walking).
Description: Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
Study NCT05733000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05733000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05733000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devimistat
Description: Receive IV
Study NCT05733000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Receive IV
Study NCT05733000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Receive IV
Study NCT05733000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Receive PO
Study NCT05197192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)
Study NCT05197192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg).
Study NCT05733000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05179096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
Study NCT02119572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer support
Study NCT02119572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual education lectures
Study NCT02119572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual education lectures
Study NCT06253520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
Study NCT06253520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT06253520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study NCT06253520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRAS TCR-Transduced PBL
Description: Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine).
Study NCT06253520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-C903/GRT-R904
Description: Day 0 (GRT-C903): Injection of 1.0 mL at each of 2 bilateral vaccine injections. Weeks 4, 8 and 12 (as applicable, GRT-R904): Injection of 0.25 mL of diluted GRT-R904 at each of 2 bilateral vaccine injections
Study NCT06233461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study NCT06233461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-279 placebo-matching capsules.
Study NCT02915198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
Study NCT02915198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo
Study NCT06243146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titration of Inspired Oxygen
Description: Titration of Inspired Oxygen During One-Lung Ventilation
Study NCT05057156 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive rehabilitation
Description: patients have to use an app with cognitive games
Study NCT05057156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive rehabilitation
Description: patients have to use an app with cognitive games
Study NCT06243146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of Inspired Oxygen
Description: Titration of Inspired Oxygen During One-Lung Ventilation
Study NCT06635525 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: Single-dose
Study NCT06312332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Embolism (PE) Care in Emergency Department (ED)
Description: Utilize implementation mapping to facilitate intervention development and evaluation that can be disseminated broadly in diverse settings. Intervention to include a structured education program for clinicians on home management of patients with low-risk PE led by regional/national leaders, the development of Clinician pre-commitment, point-of-care nudge including a clinical guideline integrated into an electronic health record clinical decision support, facilitated medication access, and dedicated outpatient rapid-follow up.
Study NCT05499364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TinCat
Description: 7-10 minute personalized video sessions based in tobacco cessation modules.